Technology | June 28, 2006

Minimally Invasive Laser Solution for Atrial Fibrillation

A 1064 nm wavelength laser technology, the Atrilaze Surgical Ablation system complements its existing 810 nm technology.
The system is indicated for delivery of laser light to soft tissue, including cardiac tissue, during surgical procedures. Indications include the incision, excision, dissection, vaporization, ablation or coagulation of soft tissue.
Because it can be delivered through a 600 micron optical fiber, the Atrilaze system is designed for very small incisions, potentially enabling a stand-alone (closed-chest, beating heart) procedure.

Related Content

REBALANCE-HF early feasibility trial met objective of identifying responder group with demonstrated benefits in heart function, hemodynamics, and physical activity at 6 months
News
Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems
News
Boston Scientific Receives FDA Approval for the POLARx Cryoablation System

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.
News
Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
The Arrhythmia Care Team at Corewell Health Celebrate First Successful Procedures With New Genesis Robotic Cardiac Ablation System from Stereotaxis.
News
Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated announced submission of pivotal clinical data from the AcQForce Flutter trial
News
Acutus Medical Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter and System

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally
News
Acutus Medical Completes Enrollment in IDE Trial with its AcQBlate FORCE Sensing Ablation System

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Denmark’s only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis’ advanced robotic technology.
News
Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
The Acutus Medical AcQBlate Force sensing ablation catheter.
News
Acutus Medical Initiates First IDE Therapy Trial With AcQBlate Force Sensing Ablation System

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
Health Canada and the U.S. Food and Drug Administration (FDA) approved Thermedical’s degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter, currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.
News
FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News
Saline Enhanced Radiofrequency Ablation May be an Effective Method to Treat Ventricular Tachycardia

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now